Cidel Asset Management’s Quest Diagnostics DGX Stock Holding History

Cidel Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Hold	1,069	–	–	0.01%	426
2026 Q1	$210K	Buy	+1,069	New	+$208K	0.01%	410

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Cidel Asset Management's DGX Position: Q2 2026 in Review

Cidel Asset Management held its Quest Diagnostics (DGX) position steady in Q2 2026 at 1,069 shares worth $227K. The position accounts for 0.01% of the portfolio, ranked #426.

Cidel Asset Management first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Cidel Asset Management held 1,069 shares of Quest Diagnostics worth $227K as of Q2 2026.
Cidel Asset Management left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up 0.01% of Cidel Asset Management's portfolio in Q2 2026, its #426 holding.
Cidel Asset Management first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Cidel Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.